All posts by imreal

North Billerica, Southbridge, and Boston’s South End


The North Billerica Bay State Physical Therapy clinic is located off of Route 129, at 199 Boston Rd. The clinic is led by Managing Partner, Michael Sheehan, PT, DPT, who received his Doctor of Physical Therapy degree from University of Massachusetts Lowell. Michael, who is also Managing Partner at Bay State Physical Therapy in Chelmsford, specializes in Sports Medicine and utilizes a hands-on approach to the treatment of injuries to the spine and extremities. After having kids of his own, he has found a passion for treating pediatric conditions.

The Southbridge clinic is located at 914 Main Street, Southbridge MA. Southbridge will be led by Managing Partner, Jim Buzzell, MSPT. Jim specializes in treating orthopedic injuries and manual therapy. As an expert in the field, Jim treats a range of conditions including neck pain, knee pain, sciatica, and pre- and post-surgical injuries. In addition to Southbridge, Jim is Managing Partner for Bay State Physical Therapy in West Brookfield and Leicester

The South End clinic is located at 631 Tremont Street, Boston, diagonally across from Heartbreak Hill Running Company. The clinic is led by Justine Beauchamp, PT, DPT, CPES, who received her Doctor of Physical Therapy degree from Simmons University. Justine, longtime Clinic Manager at Bay State Physical Therapy in South Boston, provides treatment to orthopedic conditions such as neck pain/headaches, sport-related injuries, lower back dysfunction, and pre- and post-surgical rehabilitation for all joints. She also specializes in treating both women and men, with pelvic floor related dysfunction.

Appointments are now available at all three Bay State Physical Therapy clinics. The offices are open Monday through Friday, with additional availability upon request. Visit our website to learn more about each location at baystatept.com.

About Cypress Health Partners

Cypress Health Partners (“CHP”), headquartered in Braintree, MA is the largest network of physical therapy and chiropractic clinics in New England. Its scale allows it to offer its clinics the resources and support they need to thrive and deliver the best possible patient experience. As CHP grows, the organization is guided by a vision that physical therapy and chiropractic treatments should be at the front line of musculoskeletal health and that it is its responsibility to help the communities live healthier and more fulfilling lives, while reducing healthcare costs and reliance on opioids to treat pain.

To learn more about partnering with Cypress Health Partners, please visit cypresshealthpartners.com or contact Brady Hill, SVP of Strategy and Corporate Development, bhill@cypresshp.com

Share article on social media or email:

Cleveland Clinic becomes national EEG reader group for Stratus


News Image

“We are excited about the addition of Cleveland Clinic’s clinical interpretation services to Stratus’ neurodiagnostic testing offering,” said Imad Najm, MD, Director, Cleveland Clinic’s Epilepsy Center.

Stratus, the country’s leading provider of EEG services and solutions, and Cleveland Clinic today announced a three-year agreement for Cleveland Clinic’s Epilepsy Center to become the National Reader Group for Stratus. The addition of Cleveland Clinic’s reader services to Stratus’ EEG testing supports both organizations’ goals of improving access to high quality medical care.

Stratus provides inpatient and ambulatory EEG services across 42 states, in both urban and rural communities. A significant number of the studies Stratus conducts are ordered by community neurologists who have not specialized in the reading of EEG data and prefer to have the study interpreted by a specialist. Under the terms of this new agreement, physicians ordering an EEG study through Stratus will have the option for Cleveland Clinic’s team of globally recognized epilepsy specialists to interpret the study and provide a professional report to them to aid in diagnosis and treatment. The interpreting physicians will also make themselves available for a peer-to-peer review of the findings with the ordering physician, if needed.

“We are excited about the addition of Cleveland Clinic’s clinical interpretation services to Stratus’ neurodiagnostic testing offering and it is a reflection of our commitment to provide other communities, providers, and patients access to our epilepsy and neurophysiology expertise,” said Imad Najm, MD, Director, Cleveland Clinic’s Epilepsy Center. “There are many areas of the country that do not have access to this type of physician expertise. By providing our epilepsy group’s services, we can help physicians across the country improve their quality of care.”

“Stratus is proud to be able to offer the expertise of Cleveland Clinic’s EEG Reader Group to the physicians that utilize our services,” said Charlie Alvarez, Chief Executive Officer of Stratus. “The fundamental goals of each of our organizations are well aligned. We both believe that patients should have access to high quality healthcare no matter where they live, including rural communities. We believe that working together we provide an enhanced level of service to physicians using our solutions, which leads to patients getting a more accurate and timely diagnosis, and as a result, the care they require to lead a better life.”

About Stratus

Stratus is the nation’s leading provider of EEG solutions and has served more than 98,000 patients across the U.S. The company offers technology, services, and proprietary software solutions to help neurologists diagnose their patients with epilepsy and other seizure-like disorders accurately and quickly. Stratus also provides mobile cardiac telemetry to support the diagnostic testing needs of the neurology community. Additionally, the company’s R&D division holds the world’s largest database of de-identified EEG recordings and is applying machine learning to improve the overall quality and efficiency of EEG testing. To learn more, visit http://www.stratusneuro.com.

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 72,500 employees worldwide are more than 5,050 salaried physicians and researchers, and 17,800 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,500-bed health system that includes a 173-acre main campus near downtown Cleveland, 21 hospitals, more than 220 outpatient facilities, including locations in northeast Ohio; southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2021, there were 10.2 million total outpatient visits, 304,000 hospital admissions and observations, and 259,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.

Share article on social media or email:



Vapor Fresh Launches Updated Version Of Plant Based Gym Wipe Canisters


Vapor Fresh, a leading manufacturer of green cleaning products for the sports & fitness industry, has launched an updated version of their Vapor Fresh Disinfecting Gym Wipe Canisters.

Since 2016, Vapor Fresh has been selling jumbo refill rolls of plant based disinfecting gym wipes to commercial gyms, community centers, college recreation centers and military bases.

In 2021, as people began using more workout equipment at home, Vapor Fresh launched a small canister version of their gym wipes to take the same plant based chemistry the top gyms were using and bring it into the home.

They recently launched an updated version of these wipe canisters with the following improvements:

  • 25% more wipes per canister
  • Price lowered from $11.99/ea to $9.99/ea
  • Hermetically sealed lid with easier dispensing of wipes
  • Improved scent
  • Stronger wipe material

There have been numerous studies that connect quaternary ammonium compounds, the active ingredient in most other cleaning products, with asthma, eczema and reproductive health concerns. Vapor Fresh is completely free of quaternary ammonium compounds.

“We’ve always believed it’s incredibly important to limit your exposure to toxic chemicals if you want to keep your body healthy and at peak performance,” said Stephen Steinberg, Founder of Vapor Fresh. “What you clean your sports & fitness equipment with will eventually come in direct and prolonged contact with your body.”

By using plant based citric acid as their active ingredient, Vapor Fresh kills 99.9% of bacteria, viruses and fungi on the surface of fitness equipment without the use of quaternary ammonium compounds.

Vapor Fresh is used by some of the most premier gyms and recreation centers around the country, including Johns Hopkins University and Georgetown University. Vapor Fresh products can be purchased at VaporFresh.com as well as Amazon.com.

Share article on social media or email:

Author Wants to Share God’s Love and Light with Readers


News Image

Author Delores J Porter finds joy and love in her relationship with God. Through the highs and lows in her life, she saw people blame tragedies as God’s will. Porter disagrees strongly with this view, and in her book “God Out of the Shadows: Book Two,” she hopes to show readers that God has no darkness in him, and he is not to blame for the bad things that happen in the world.

“God Out of the Shadows” is a deep dive into the Bible and its true teachings. It addresses where modern Christian theology came from, and where it has been confused or distorted from God’s intended meaning. Utilizing evidence from the Bible, Porter wants to show readers that God loves every human being the same, and accepts all who will believe in him.

“It is time that people know the truth about God,” Porter said. “I started writing ‘God Out of the Shadows’ on Easter, 2020, to show people his love and grace and that he is always there to hear their whispered prayer to save, heal, deliver and protect. All good gifts come from the father above.”

Porter hopes that her book will help readers understand that God has never orchestrated adversities in anyone’s life.

“God’s true character that Jesus taught has been distorted and Satan laughs while God gets the blame for his own dirty works,” Porter said. “I believe the fables that got into the foundation of Christianity, back in the dark ages and continued in our Bible colleges, have stolen the truth about God, which has stolen our faith and miracles.”

Through her book, Porter looks to share what she has found to be God’s true teachings and hopes that readers will find a renewed love and relationship with God.

“God Out of the Shadows: Book Two”

By Delores J. Porter

ISBN: 9781669806035 (softcover); 9781669806028 (electronic)

Available at Xlibris, Amazon and Barnes & Noble

About the author

By occupation, Delores J. Porter is a hairstylist, and treasures the special moments with her clients and friends. Besides being an author, she has been a teacher and songwriter. It has always been her desire and joy to pray with people, first sharing with them that “God is love, and in him is no darkness at all,” “All good gifts come from the Father,” and “God has no respect of persons. What he does for one, he will do for all.” She has earned a two-year college diploma in theology and believes that the Holy Spirit should be everyone’s true teacher.

To learn more, please visit https://www.xlibris.com/en/bookstore/bookdetails/835932-god-out-of-the-shadows.

###

General Inquiries:            

LAVIDGE – Phoenix                        

Ashley Fletcher

afletcher@lavidge.com

Share article on social media or email:

The Yorkshire Enhanced Stop Smoking Study (YESS)


Professor Rachael Murray, of the University of Nottingham, U.K.

“The presence of a co-located stop smoking service and offer of immediate, opt-out delivery of behavioral and pharmacological support for quitting results in a high uptake by people who smoke and attended a lung screening event,” said Professor Rachael Murray, of the University of Nottingham, U.K

Patients with lung cancer who attended a lung cancer screening event and who then participated in a personalized smoking cessation study achieved smoking abstinence rates of more than 30 percent, according to research presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Many participants who undergo lung cancer screening continue to smoke and while screening offers a teachable moment for smoking cessation, there is little data to demonstrate what approach to smoking cessation is most effective.

To test the effectiveness of a personalized approach, United Kingdom-based researchers developed the Yorkshire Enhanced Stop Smoking (YESS) trial, which offered stop smoking support on an opt-out basis to all eligible smokers attending a lung health check event, which included low-dose CT screening.

The YESS trial is a double-blind randomized controlled trial comparing an enhanced, personalized smoking cessation support program that includes a booklet containing CT images of the participants’ own heart and lungs, annotated where appropriate to highlight emphysema or coronary artery calcification with accompanying explanatory text, and scripted behavioral support delivered by a trained smoking cessation practitioner, with continued standard best practice.

The primary outcome is seven-day point prevalent (self-reported) carbon monoxide validated cessation three-months after the lung health check event and two-months after recruitment into the YESS trial. Secondary outcomes include carbon monoxide validated cessation at four weeks and 12 months, and self-reported cessation at four weeks, three months and 12 months following the event.

During a lung health check event, 2150 people who reported a history of smoking were offered the opportunity to see a smoking cessation professional. Of these, 1905 (88.6 %) accepted the referral and 1609 accepted ongoing support. The seven-day validated abstinence rate in those accepting support was 16.5% as measured four weeks after the lung health check event (12,4 % of all eligible smokers). Of those who attended the lung health check event, 1003 smokers participated in the YESS trial (mean age 65 years, 50% male, 96% White, 39.1% in the lowest deprivation quintile) and 52.5% of these patients were allocated to the intervention group.

Validated seven-day abstinence rates were 33.6% in the intervention group, 30.0% in the control group (unadjusted OR 1.17, 95% CI 0.90-1.54) at 3-months post-LHC and 29.2% and 28.6% (unadjusted OR 1.03, 95% CI 0.78-1.36) at 12-months post-LHC. Subgroup analyses indicated a significant gender interaction at 3- and 12-months (p=0.002 and p=0.001 respectively), with the intervention effective in females (3-months abstinence rates among female participants were 33.9% in the intervention vs. 23.1% in the control, unadjusted OR 1.70, 95%CI 1.15-2.53). There was no significant effect of booklet content (presence/absence of emphysema or CAC) on quit rates.

“The presence of a co-located stop smoking service and offer of immediate, opt-out delivery of behavioral and pharmacological support for quitting results in a high uptake by people who smoke and attended a lung screening event,” said Professor Rachael Murray, of the University of Nottingham, U.K. “Quit rates were considerably higher three-months after the lung health check regardless of adding the personalized intervention, reinforcing the need for continued support.”

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/

Share article on social media or email:

Over 40 Board Certified Ophthalmologists at PRISM Vision Group® Have Been Reviewed & Approved By NJ Top Docs


PRISM Vision Group

NJ Top Docs has reviewed and approved more than forty board-certified ophthalmologists at PRISM Vision Group for 2022. With PRISM Vision Group’s locations spread across New Jersey, you can find a reviewed and approved NJ Top Doc everywhere you go. The group currently has office locations in Atlantic, Essex, Mercer, Middlesex, Monmouth, Morris, Ocean, Passaic, Somerset, and Union county.

PRISM Vision Group is a physician-led organization that aligns with high-quality providers who share the common goal of delivering excellent ophthalmologic service.

“PRISM Vision Group is incredibly proud of our distinguished team of physicians,” states PRISM COO, Kyle Snook.

He continues “Our best-in-class physicians exemplify PRISM’s mission to provide patients with world-class, comprehensive eye-care. From cataract and retina surgeons, glaucoma specialists, pediatric ophthalmologists to ocular plastics specialists, day in and day out they provide unrivaled outcomes and patient experience. Congratulations to our NJ physicians for their clinical excellence and advancing PRISM’s vision to be America’s premiere, independent, integrated eye care organization, now and 100 years from now.”

Below is a full list of all approved NJ Top Docs who are a part of PRISM Vision Group.


  • Joanna Pruzon – Bloomfield Eye Associates
  • Stephen H. Uretsky – Coastal Jersey Eye Center
  • Paul Liva – Hackensack Eye Care Center
  • Donald J. Cinotti – Hudson Eye Physicians and Surgeons, LLC
  • William H. Constad – Hudson Eye Physicians and Surgeons, LLC
  • Scott M. Walsman – Hudson Eye Physicians and Surgeons, LLC
  • Priya Desai – Matossian Eye Associates
  • Sebastian Lesniak – Matossian Eye Associates
  • Ilya Rozenbaum – Matossian Eye Associates
  • Elizabeth Tegins – Matossian Eye Associates & NJ Retina
  • Joseph P. Shovlin – Matossian Eye Associates & Outlook Eyecare
  • Nneka Brooks – NJ Retina
  • Nicholas Chinskey – NJ Retina
  • Leonard Feiner – NJ Retina
  • Howard F. Fine – NJ Retina
  • Eric S. Friedman – NJ Retina
  • Paul Hahn – NJ Retina
  • Vincent Ho – NJ Retina
  • Bruce J. Keyser – NJ Retina
  • David Y. Kim – NJ Retina
  • Jennifer Krawitz – NJ Retina
  • Steven A. Madreperla – NJ Retina
  • Stuart W. Noorily – NJ Retina
  • Jonathan L. Prenner – NJ Retina
  • Daniel B. Roth – NJ Retina
  • Christopher M. Seery – NJ Retina
  • Sumit P. Shah – NJ Retina
  • Vinod B. Voleti – NJ Retina
  • Harold M. Wheatley – NJ Retina
  • Patricia Cucci – North Jersey Eye Associates
  • Colleen M. Coleman – Outlook Eyecare
  • Noah B. Saipe – Outlook Eyecare
  • Patricia A. Burke – Ridgewood Eye Associates
  • John R. Stabile – Tenafly Eye Associates, PA
  • Barnard A. Kaplan – The Eye Associates and Surgicenter of Vineland
  • Debra Prieto – The Eye Associates and Surgicenter of Vineland
  • Sydney Tyson – The Eye Associates and Surgicenter of Vineland
  • Joel Confino – The Eye Care & Surgery Center
  • Ivan H. Jacobs – The Eye Care & Surgery Center
  • Milton Kahn – The Eye Care & Surgery Center
  • Dipal Shah – The Eye Care & Surgery Center

To learn more about these reviewed and approved NJ Top Docs, please visit: https://njtopdocs.com/nj-doctors/prismvisiongroup

—-

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



Allie M. French’s newly released “Wings” is a charming tale of a mischievous angel who can’t quite seem to fit in with the other angels


News Image

“Wings”: a creative story of Earth’s creation. “Wings” is the creation of published author Allie M. French, a dedicated wife and mother with a passion for the creative arts.

French shares, “in the beginning, God created the heavens and the earth. Everything He did was perfect and good. But what else was happening in Heaven during creation?

“Meet Wings, a mischievous angel working hard to earn his wings—a goal he just can’t see happening. His robes are torn, and he always seems to be in trouble. A mysterious room with a blue floating sphere will change all that. Little does he know he will take part in the creation of something wonderful!

“Wings brings imagination and creativity to children while learning about God’s creation of the earth. Wings teaches children that God created each and every one of us exactly as He wanted, flaws and all. He sees our personalities as perfect, and each individual is fully loved by Him. God’s Spirit lives in each and every one of us.”

Published by Christian Faith Publishing, Allie M. French’s new book will delight and entertain as young readers get to know a special little angel named Wings.

French shares with readers a relatable character that truly brings God’s intentions for His creation to life within the pages of this vibrant work.

Consumers can purchase “Wings” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Wings,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Refreshing Self-Help Book Teaches You The Critical Importance of Pushing The Next Generation Forward


News Image

I believe that everyone has a purpose in life and part of that purpose is to make life better for the next generations.

Author Kwamane O. Harris challenges readers to understand the importance of learning from past mistakes to encourage others in Pushing the Generations Forward: Finding Your Purpose Through the Next Generation ($13.99, paperback, 9781662855733; $5.99, e-book, 9781662855740).

This compelling book from Harris is for anyone who needs take the first step in discovering their true purpose in life. He believes that a life without purpose is a life that leaves one feeling empty and useless. He provides hope to readers that the best way to find their purpose is through the next generation. In fact, the outcome of the next generation is a direct result of how the first generation moves away from a life of “surviving” to a life of “thriving.”

Adopting the concept of “pushing the generations forward” is a much-needed mental shift that goes beyond current thought systems. No matter where one finds themself in life today, there is a responsibility to learn from past mistakes, face every generational curse and break the generational traumas that may have plagued a family line for centuries. Harris includes thought-provoking and relevant issues such as spirituality, racism, oppression, mental health, purpose, growth and fixed mindsets, brain science and resilience. After reading this book, readers will push the next generation into a life of thriving, a life filled with opportunities and a fulfilling life of true purpose.

When asked what inspired the author to write this book, Harris said, “I believe that everyone has a purpose in life and part of that purpose is to make life better for the next generations.”

Harris holds a bachelor’s degree in Criminal Justice, a master’s degree in Business Administration and is a Certified Professional Life Coach. He was the recipient of Utah’s “Business Magazine Top 20 in their 20’s” award. He has been supporting at risk youth and families for the last 15 years and possesses a proven ability to engage youth and families through advocacy, civic engagement and evidence-based prevention programming. Most recently, Harris worked with the United Nations Civil Society Youth Committee that led outreach initiatives for the 68th Civil Society Conference, which was attended by 2,000 representatives from more than 500 civil society organizations from over 100 countries. Harris loves spending time with his wife, family and friends. He also enjoys sports and mountain biking.

###

Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 15,000 titles published to date. Pushing the Generations Forward: Finding Your Purpose Through the Next Generation is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.

Share article on social media or email:

NELSON Trial Protocol More Sensitive than NLST and May Increase the Benefits of Lung Cancer Screening, While Reducing Unnecessary Follow-up Procedures


Koen de Nijs, Erasmus University Medical Center Rotterdam, the Netherlands.

“The protocol used in NELSON was more sensitive than the protocol used in the NLST, particularly for early-stage cancers. Furthermore, the protocol used in NELSON also had improved specificity.” — Koen de Nijs, Erasmus University Medical Center Rotterdam, the Netherlands.

The protocol used to screen and detect lung cancer in the NELSON Trial is more sensitive than the protocol used in the National Lung Cancer Screening Trial, particularly for early-stage cancers, according to research reported today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

The Dutch-Belgian lung cancer screening trial (Nederlands-Leuvens Longkanker Screenings Onderzoek [NELSON]) demonstrated a reduction in lung cancer mortality of 24% for screening with low-dose computed tomography (CT), compared to the 20% found in the National Lung Screening Trial.

The NELSON and NLST differed in study population and trial design. Specifically, in contrast to the NLST, the NELSON trial employed a nodule management protocol that incorporated nodule volume and quantified volume growth as opposed to nodule diameter.

“We evaluated how the difference in nodule management protocols affected the CT sensitivity across stage and histology in the trials,” said Koen de Nijs, Erasmus University Medical Center Rotterdam, the Netherlands. In cancer screening, sensitivity is the ability of a screening method to detect cancer while it is still in the pre-clinical phase.

Mr. De Nijs and colleagues from the NELSON consortium employed the MISCAN-Lung model, previously used to evaluate the results of the NLST, to evaluate the outcomes of the NELSON trial. The model was used to reproduce lung cancer incidence and mortality by method of detection (clinical or screen-detected), sex, histology and stage.

“We evaluated the potential differences in CT sensitivity by stage and histology, after accounting for the characteristics of the study population, trial design and lung cancer epidemiology in each trial,” he reported. For both trials, de Nijs considered a screening result a true positive when lung cancer was detected through the screening CT and related follow-up procedures.

Furthermore, previous research has shown that the protocol used in NELSON also had improved specificity. Nodule management protocols based on volumetry are therefore likely to increase the benefits of lung cancer screening, while reducing unnecessary follow-up procedures.

Mr. de Nijs found that the sensitivity in NELSON was estimated to be higher across all stages compared with the NLST. In particular, CT sensitivity was considerably higher for early-stage adenocarcinoma (for stage 1A, 73% in NELSON over 57% in the NLST, for stage 1B, 90% in NELSON vs 64% in the NLST) and stage 2 squamous cell carcinoma (75% in NELSON over 39% in the NLST).

“Model-based comparison of the NELSON and NLST suggests that the differences in screening effectiveness may be explained by differences in the nodule management protocols,” said Mr. de Nijs. “The protocol used in NELSON was more sensitive than the protocol used in the NLST, particularly for early-stage cancers. Furthermore, the protocol used in NELSON also had improved specificity.”

Mr. de Nijs reported that nodule management protocols based on volumetry are likely to increase the benefits of lung cancer screening, while reducing unnecessary follow-up procedures.

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/

Share article on social media or email:

IASLC Early Detection and Screening Committee to Report on Global Obstacles to Lung Cancer Screening


Dr. Milena Cavic, Institute for Oncology and Radiology of Serbia

“Many countries are planning to introduce lung cancer screening, taking into account all the governmental, healthcare and population-specific parameters is important for this delicate process.” – Dr. Milena Cavic, Institute for Oncology and Radiology of Serbia.

Today, representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee announced an effort to outline the current obstacles and perspectives of lung cancer screening in low- and middle-income countries and to propose guidance, recommendations, and future research strategies.

The Diagnostics Working Group of the IASLC Early Detection and Screening Committee currently has six members from low-and middle-income countries from four continents (Brazil, China, Colombia, India, Serbia, South Africa) and 11 members from high-income countries from three continents (Canada, Germany, Hungary, Italy, Spain, South Korea, UK, United States). These countries provided specific data from these countries/regions and data from other countries were evaluated by literature review, exploring the JTO Lung Cancer Worldwide manuscript series, official epidemiological global data and other sources.

Working Group meetings lead to observations that for a systematic evaluation of the status of lung cancer screening in low-to middle-income countries, a comprehensive comparison of lung cancer incidence and mortality by stage at diagnosis would need to be conducted between low-to middle-income and high-income countries.

“Furthermore, specific risks for lung cancer in the specific regions have to be taken into account,” said Dr. Milena Cavic, Institute for Oncology and Radiology of Serbia. Dr. Cavic reported that factors that give rise to challenges in LC screening implementation include those of political and financial nature, as well as healthcare system overload with other programs and competing priorities, reimbursement rules and various population-specific risk factors. The availability of adequate infrastructure (CT scanners, qualified radiologists, pulmonologists, thoracic surgeons and radiotherapists, CT- and bronchoscopic biopsy services) and availability of skilled health care personnel for post screening diagnostic work-up were also determined to be crucial factors.

The Diagnostics WG determined that from its six present low-to middle-income countries, three (Brazil, China and Colombia), had structured, institutional lung cancer screening programs, while 1 had a regional pilot program (Serbia). In the high-income countries groups, members reported different forms of structured screening programs (national/regional population-based screening programs, or research studies). To fully explore the perspectives of implementing lung cancer screening in low-to middle-income countries, the cost/benefit ratio would need to be carefully evaluated in each country, considering evidence-based data and regional specificities. The ED&S Committee has several ongoing initiatives that aim to address this issue.

“Broader discussion on this matter is globally important, both for low-to middle-income and high-income countries. Many countries are planning to introduce lung cancer screening, taking into account all the governmental, healthcare and population-specific parameters important for this delicate process, thus evidence-based guidelines are of outmost importance,” Dr. Cavic said.

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/.

Share article on social media or email: